Literature DB >> 22922419

Development of fully amorphous dispersions of a low T(g) drug via co-spray drying with hydrophilic polymers.

Min Zhao1, Susan A Barker, Peter S Belton, Caroline McGregor, Duncan Q M Craig.   

Abstract

The aim of the study was to prepare molecular dispersions of a physically highly unstable amorphous drug, paracetamol (acetaminophen with a T(g) of ca. 25°C) via co-spray drying with a variety of polymers. Solid dispersions at a range of drug loadings (10-90%w/w) using hydroxypropyl methylcellulose/acetate succinate (HPMC/HPMC AS), polyvinylpyrrolidone (PVP) and copovidone were produced and characterised by modulated temperature differential scanning calorimetry (MTDSC), thermogravimetric analysis (TGA), X-ray powder diffraction (XRPD), Fourier transform infrared spectroscopy (FTIR) and scanning electron microscopy (SEM). PVP-based polymers showed a greater tendency than the HPMC-based group to generate temperature-stable dispersions. In particular, copovidone (Plasdone® S-630) was found to be the most effective of the polymers studied and could formulate molecular dispersions at drug loadings up to and including 40%w/w. However, no evidence for direct drug-polymer interactions was found for such systems as a possible stabilising mechanism. The expected relationship of a higher T(g) of the polymer leading to greater stabilisation was not observed, while there was an inverse relationship between viscosity grade and amorphous phase generation. The study has therefore shown that temperature-stable amorphous dispersions of a low T(g) drug may be prepared by co-spray drying, particularly using PVP-based polymers.
Copyright © 2012 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22922419     DOI: 10.1016/j.ejpb.2012.07.012

Source DB:  PubMed          Journal:  Eur J Pharm Biopharm        ISSN: 0939-6411            Impact factor:   5.571


  7 in total

1.  In vitro and in vivo performance of dry powder inhalation formulations: comparison of particles prepared by thin film freezing and micronization.

Authors:  Yi-Bo Wang; Alan B Watts; Jay I Peters; Sha Liu; Ayesha Batra; Robert O Williams
Journal:  AAPS PharmSciTech       Date:  2014-05-14       Impact factor: 3.246

Review 2.  Beneath the Skin: A Review of Current Trends and Future Prospects of Transdermal Drug Delivery Systems.

Authors:  Ahlam Zaid Alkilani; Jehad Nasereddin; Rania Hamed; Sukaina Nimrawi; Ghaid Hussein; Hadeel Abo-Zour; Ryan F Donnelly
Journal:  Pharmaceutics       Date:  2022-05-28       Impact factor: 6.525

3.  Improved oral absorption and anti-lung cancer activity of paclitaxel-loaded mixed micelles.

Authors:  Jian Hou; E Sun; Zhen-Hai Zhang; Jing Wang; Lei Yang; Li Cui; Zhong-Cheng Ke; Xiao-Bin Tan; Xiao-Bin Jia; Huixia Lv
Journal:  Drug Deliv       Date:  2017-11       Impact factor: 6.419

4.  Glucosamine-paracetamol spray-dried solid dispersions with maximized intrinsic dissolution rate, bioavailability and decreased levels of in vivo toxic metabolites.

Authors:  Ahmed Mahmoud Abdelhaleem Ali; Ahmed Khames; Majed Mansour Alrobaian; Mohammad Hamaidi; Mohammed As Abourehab
Journal:  Drug Des Devel Ther       Date:  2018-09-21       Impact factor: 4.162

5.  Direct Granule Feeding of Thermal Droplet Deposition 3D Printing of Porous Pharmaceutical Solid Dosage Forms Free of Plasticisers.

Authors:  Thomas McDonagh; Peter Belton; Sheng Qi
Journal:  Pharm Res       Date:  2022-02-22       Impact factor: 4.200

6.  Solubility and bioavailability enhancement of poorly aqueous soluble atorvastatin: in vitro, ex vivo, and in vivo studies.

Authors:  Madhuri S Rodde; Ganesh T Divase; Tejas B Devkar; Avinash R Tekade
Journal:  Biomed Res Int       Date:  2014-06-03       Impact factor: 3.411

7.  Molecular Disorder of Bicalutamide-Amorphous Solid Dispersions Obtained by Solvent Methods.

Authors:  Joanna Szafraniec; Agata Antosik; Justyna Knapik-Kowalczuk; Karolina Gawlak; Mateusz Kurek; Jakub Szlęk; Witold Jamróz; Marian Paluch; Renata Jachowicz
Journal:  Pharmaceutics       Date:  2018-10-18       Impact factor: 6.321

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.